Understand and Predict Immunogenicity in Combination Therapies

In this poster, we demonstrate how a Quantitative Systems Pharmacology (QSP) platform is utilized to predict the development of anti-drug antibodies (ADA) and pharmacokinetic (PK) impacts in biotherapeutic combinations. This study focuses on immunotherapy agents nivolumab and ipilimumab, and explores the role of T regulatory cells (Tregs) in ADA induction. Learn how this extended modeling approach can support more accurate clinical immunogenicity predictions and inform drug development strategies.